1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Argentina Pharmaceuticals and Healthcare Report Q3 2015

Argentina Pharmaceuticals and Healthcare Report Q3 2015

  • May 2015
  • -
  • Business Monitor International
  • -
  • 137 pages

Includes 3 FREE quarterly updates

BMI View:
Argentina's pharmaceuticals and healthcare sector is expected to experience improved growthrates through the next decade, standing slightly behind growth patterns in the other large markets in LatinAmerica. Combined with expected improvements in the Argentinean business environment to take placewith the next government administration since 2016, risks to our pharmaceuticals and healthcare forecastsare weighted to the upside. However, we expect a more mixed market growth picture through the rest of2015, with expansionary fiscal policy ahead of general elections not able to offset modest consumerconfidence. More broadly, lax intellectual property protection will continue to hinder the pharmaceuticalmarket potential while deterring more significant levels of foreign investment.
Headline Expenditure Projections
Pharmaceuticals: ARS49.89bn (USD6.09bn) in 2014 to ARS54.63bn (USD5.67bn) in 2015; +7.3% inlocal currency terms and -6.9% in US dollar terms. Forecast broadly in line with the previous quarter.Healthcare: ARS278.35bn (USD33.94bn) in 2014 to ARS304.07bn (USD32.18bn) in 2015; +9.2% in localcurrency terms and -5.2% in US dollar terms. Forecast broadly in line with the previous quarter.

Table Of Contents

Argentina Pharmaceuticals and Healthcare Report Q3 2015
BMI Industry View ...... 7
SWOT ............ 9
Political .......... 11
Economic ........ 12
Operational Risk ............. 13
Industry Forecast ..... 15
Pharmaceutical Market Forecast ....... 15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Argentina 2011-2019) . . . . 17
Healthcare Market Forecast ............. 18
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Argentina 2011-2019) . . . . . 19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Argentina 2011-2019) . . . 20
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Argentina 2011-2019) . . . 20
Prescription Drug Market Forecast ... 21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Argentina 2011-2019) . . . . . 22
Patented Drug Market Forecast ........ 23
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Argentina 2011-2019) . . . 25
Generic Drug Market Forecast ......... 26
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Argentina 2011-2019) . . . . 28
OTC Medicine Market Forecast ........ 29
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Argentina 2011-2019) . . . . . 31
Pharmaceutical Trade Forecast ........ 31
Table: Pharmaceutical Trade Data And Forecasts (Argentina 2013-2019) . . . 33
Table: Pharmaceutical Trade Data And Forecasts local currency (Argentina 2013-2019) . . . . . 34
Key Risks To BMI's Forecast Scenario 34
Macroeconomic Forecasts ..... 36
Economic Analysis ........... 36
Table: Economic Activity (Argentina 2010-2019) 41
Industry Risk Reward Ratings 42
Americas Risk/Reward Index ............ 42
Argentina Risk/Reward Index ............ 47
Rewards ........ 48
Risks ............. 48
Market Overview ...... 50
Industry Trends And Developments ..... 52
Epidemiology . 52
Healthcare ..... 53
Healthcare Insurance ...... 54
Medical Tourism ............ 56
Table: Health Status 57
Table: Healthcare Funding . . . . . 57
Table: Healthcare Resources (Argentina 2009-2014) . . 58
Table: Healthcare Personnel (Argentina 2009-2014) . . 58
Table: Healthcare Activity (Argentina 2009-2014) . . . . . 59
Research and Development 59
Table: Pharmaceutical RandD Investment, 2001-2007 . . 60
Clinical Trials 63
Regulatory Development ........ 65
Table: Product Registration, Annex I and II Listed Countries 66
Intellectual Property Environment .... 72
Pricing and Reimbursement 76
Table: Pharmaceutical Price Build-Up . . . . 77
Table: Taxes Paid By The Pharmaceutical Industry By Type, 2005-2007 (ARSmn) 78
Table: Drug Price Freeze, 2005-2008 . . . . . 79
Reimbursement Regime ... 79
Other Regulatory Issues .. 80
Competitive Landscape .......... 83
Research Based Industry . 84
Generic Drugmakers ...... 87
Recent Company Developments ....... 89
Pharmaceutical Wholesale Sector .... 92
Retail Pharmacy Sector ... 93
Company Profile ....... 97
Roemmers ....... 97
Laboratorios Bago ......... 101
Novartis ........ 105
Boehringer Ingelheim ..... 108
Merck and Co ... 111
GlaxoSmithKline ........... 114
Roche ........... 117
Sanofi ........... 120
Pfizer ........... 123
Demographic Forecast ......... 126
Table: Population Headline Indicators (Argentina 1990-2025) . . 127
Table: Key Population Ratios (Argentina 1990-2025) 127
Table: Urban/Rural Population and Life Expectancy (Argentina 1990-2025) . . 128
Table: Population By Age Group (Argentina 1990-2025) . . . 128
Table: Population By Age Group % (Argentina 1990-2025) 129
Glossary ... 131
Methodology ........... 133
Pharmaceutical Expenditure Forecast Model .. 133
Healthcare Expenditure Forecast Model ......... 133
Notes On Methodology .. 134
Risk/Reward Index Methodology .... 135
Index Overview ............ 136
Table: Pharmaceutical Risk/Reward Index Indicators 136
Indicator Weightings .... 137

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Glaucoma - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Glaucoma - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • May 2015
  • by Global Data

PharmaPoint: Glaucoma - Global Drug Forecast and Market Analysis to 2023 Summary Glaucoma is a leading cause of preventable blindness globally. This chronic progressive optic neuropathy causes irreversible ...

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • May 2015
  • by Global Data

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2023 Summary GlobalData estimates that the total market size for the 8MM in 2013 was $15.4bn, comprised of $11.0bn in branded drug ...

Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products

Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products

  • $ 6 650
  • Industry report
  • May 2015
  • by BCC Research

This BCC Research study provides an in-depth analysis and forecast of selected areas of the global healthcare acquired infections (HAI) market. The report offers forecasts by treatment segment and type ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.